Defactinib

• Description:

  Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.

• Product Name Alternative:

  VS-6063; PF-04554878

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  FAK

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Defactinib.html

• Purity:

  99.74

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(NC)C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=NC=CN=C3N(C)S(=O)(C)=O)=N2)C=C1

• Molecular Formula:

  C20H21F3N8O3S

• Molecular Weight:

  510.49

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105 (19) :1485-95.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Appl Mater Interfaces. 2024 Oct 16;16 (41) :55130-55141.|ACS Nano. 2023 Jan 4;17 (2) :1036-1053.|Atherosclerosis. 2025 Apr 8:404:119190.|Biochem Biophys Res Commun. 2024 Sep 17:725:150236.|bioRxiv. 2024 November 26.|bioRxiv. 2025 May 19:2025.05.15.654389.|Bone. 2022 Jan:154:116231.|Cancer Commun (Lond) . 2024 Oct;44 (10) :1106-1129.|Cancer Sci. 2025 Aug 13.|Cell Death Dis. 2021 Sep 23;12 (10) :868.|Cell Mol Gastroenterol Hepatol. 2021;11 (3) :683-696.|Cell Signal. 2025 Jun 17:111946.|Clin Breast Cancer. 2024 Jun;24 (4) :e244-e257.e1.|EMBO J. 2025 Mar;44 (5) :1464-1487.|Exp Cell Res. 2021 Nov 15;408 (2) :112868.|Exp Ther Med. 2020 Aug;20 (2) :1405-1414.|Front Oncol. 2022 Apr 28;12:851065.|Heliyon.2024 Aug 6;10 (16) :e35727.|J Exp Clin Cancer Res. 2018 Jul 28;37 (1) :175.|J Exp Clin Cancer Res. 2022 Sep 16;41 (1) :275.|J Int Med Res. 2018 Apr;46 (4) :1311-1325. |J Orthop Transl. 2020 May 19;24:12-22.|J Transl Med. 2023 Sep 19;21 (1) :640.|Mol Carcinog. 2024 Jan;63 (1) :173-189.|Nat Commun. 2023 Apr 29;14 (1) :2478.|Nat Commun. 2025 Sep 29;16 (1) :8541.|Nat Commun. 2019 Aug 16;10 (1) :3708. |Oncogene. 2023 Apr;42 (15) :1166-1180.|Oncogene. 2024 Sep;43 (39) :2951-2969.|Oncol Res. 2024 Mar 20;32 (4) :679-690.|Phytomedicine. 2022 Oct:105:154349.|Placenta. 2024 Aug 21:156:30-37.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Print. September 13th, 2022.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2019 May 20;9 (1) :7617.|Sci Rep. 2025 May 6;15 (1) :15780.|Science. 2017 Dec 1;358 (6367) :eaan4368.|University of Otago. 2025 Oct 7.|University of Zürich. Department of Dermatology. 2021 Dec.|Bioact Mater. 2021 Jul 1:8:109-123.|Bioact Mater. 2021 Jun 1:7:364-376.|bioRxiv. 2023 Oct 23:2023.03.01.530599.|bioRxiv. 2025 Jul 26:2025.07.22.666009.|Cell Mol Gastroenterol Hepatol. 2025 May 29:101548.|Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110221.|Mol Biomed. 2025 Nov 24;6 (1) :116.|Mol Metab. 2023 Apr:70:101698.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2021 Aug.

• CAS Number:

  [1073154-85-4]